Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sow Estrus Detection Based on the Fusion of Vulvar Visual Features.

Animals : an open access journal from MDPI·2025
Same author

Molecular Epidemiology and Genetic Evolution of Porcine Reproductive and Respiratory Syndrome Virus in Northern China During 2021-2023.

Viruses·2025
Same author

Effects of Dietary Modified Bazhen on Reproductive Performance, Immunity, Breast Milk Microbes, and Metabolome Characterization of Sows.

Frontiers in microbiology·2021
Same author

A narrative review of the roles of muscle segment homeobox transcription factor family in cancer.

Annals of translational medicine·2021
Same author

Enhanced Catalysis of P-doped SnO<sub>2</sub> for the V<sup>2+</sup>/V<sup>3+</sup> Redox Reaction in Vanadium Redox Flow Battery.

Frontiers in chemistry·2021
Same author

Fully automated pelvic bone segmentation in multiparameteric MRI using a 3D convolutional neural network.

Insights into imaging·2021

Related Experiment Video

Updated: Jun 21, 2026

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Yak interferon-alpha loaded solid lipid nanoparticles for controlled release.

Shaoyong Li1, Baokai Zhao, Fenghua Wang

  • 1Department of Preventive Veterinary Medicine, College of Veterinary Medicine, China Agricultural University, Beijing 100193, PR China.

Research in Veterinary Science
|August 4, 2009
PubMed
Summary

This study developed yak interferon-alpha (IFN-alpha) solid lipid nanoparticles (SLN) for sustained drug delivery. The IFN-alpha SLN demonstrated effective antiviral activity and controlled release over 16 days, showing potential for veterinary therapeutics.

More Related Videos

Intra-lymph Node Injection of Biodegradable Polymer Particles
09:06

Intra-lymph Node Injection of Biodegradable Polymer Particles

Published on: January 2, 2014

Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications
08:19

Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications

Published on: November 17, 2015

Related Experiment Videos

Last Updated: Jun 21, 2026

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Intra-lymph Node Injection of Biodegradable Polymer Particles
09:06

Intra-lymph Node Injection of Biodegradable Polymer Particles

Published on: January 2, 2014

Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications
08:19

Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications

Published on: November 17, 2015

Area of Science:

  • Veterinary Medicine
  • Biotechnology
  • Drug Delivery Systems

Background:

  • Interferon-alpha (IFN-alpha) is crucial for antiviral responses.
  • Controlled release formulations are needed for effective veterinary therapeutics.
  • Yak IFN-alpha offers potential for animal health applications.

Purpose of the Study:

  • To develop and characterize solid lipid nanoparticles (SLN) for controlled release of yak interferon-alpha (IFN-alpha).
  • To evaluate the in vitro antiviral activity and release profile of IFN-alpha-loaded SLN.
  • To assess the safety and potential of this formulation for veterinary use.

Main Methods:

  • Recombinant yak IFN-alpha was expressed in Escherichia coli and purified.
  • IFN-alpha was encapsulated into SLN using a double emulsion solvent evaporation method.
  • Particle size, zeta potential, encapsulation efficiency, and loading capacity were determined.
  • In vitro release, antiviral assays, and cytotoxicity tests were performed.

Main Results:

  • IFN-alpha-loaded SLN exhibited a particle size of 124.2 nm and zeta potential of -11.2 mV.
  • High encapsulation efficiency (83.7%) and loading capacity (1.73%) were achieved.
  • The SLN demonstrated a 16-day sustained release of IFN-alpha with significant antiviral activity against VSV in MDBK cells.
  • Cytotoxicity assays confirmed the safety of the SLN formulation.

Conclusions:

  • Yak IFN-alpha-loaded SLN provide a promising formulation for sustained drug delivery in veterinary medicine.
  • The developed SLN formulation is non-toxic and exhibits sustained release of bioactive IFN-alpha.
  • This approach holds potential for enhanced treatment strategies in animal health.